Clinical Trial Update: Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial investigating Folfirinox with stereotactic body radiation therapy in advanced, non-resectable pancreatic cancer has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer Non-resectable

Drugs mentioned

• FOLFIRINOX

Snippet

Sponsor: University of Louisville | Conditions: Pancreatic Cancer Non-resectable | Phase 2 | Status: COMPLETED | Results posted: 2024-03-05